| ROCKET PHARMACEUTICALS |
| USA |
| Gesundheit |
| US77313F1066 / A2JA9Q |
| 9IP1 (Frankfurt) / RCKT (NASDAQ) |
| FRA:9IP1, ETR:9IP1, 9IP1:GR, NASDAQ:RCKT |
| - |
| https://www.rocketpharma... |
|
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built aro..
>Volltext.. |
| 326.35 Mio. EUR |
| 99.41 Mio. EUR |
| - |
| -157.9 Mio. EUR |
| -14.95 Mio. EUR |
| -0.14 EUR |
| 21.49 Mio. EUR |
| 194.59 Mio. EUR |
| -147.59 Mio. EUR |
| 9.06 |
| - |
| 93.08% |
| - |
| - |
| - |
| ROCKET PHARMACEUTICALS, ROCKET PHARMA, ROCKET PHARMACEUTICAL |
| 16.09.26 |
|
||||
|